On this week’s episode of DNA Today, we are joined by 2 scientists from Phase Genomics. Dr. Ivan Liachko is the Founder and CEO of Phase Genomics and has worked in the genetic/genomic research field for over 20 years. He has authored over 20 peer reviewed papers and created multiple patents specializing in the field of microbial genomics and synthetic biology. Dr. Liachko is one of the original inventors of the Hi-C assembly and metagenomic deconvolution and has over a decade of experience in scientific management and mentorship. He received his PhD from Cornell University. Our other guest is Dr. Stephen Eacker, VP of Research and Development for Phase Genomics, who is also a lifelong scientist. Prior to starting his role as VP, he served as a Senior Research Scientist and was part of the faculty at Johns Hopkins University where he was the Principal Investigator of a laboratory focused on using the ribosome as a platform for understanding neurobiology. He received his PhD from the University of Washington in Genome Sciences/Genomics. On This Episode We Discuss: Next generation cytogenomic technologies like CytoTerra and OncoTerra Why ultra-long-range sequencing is advantageous compared to other approaches Types of chromosomal abnormalities that can be identified with this technology Identifying genetic changes that lead to pregnancy losses and how identifying these changes can help with future pregnancies How researchers can get early access to CytoTerra Interested in today’s episode topic? Watch this webinar from Phase Genomics about next generation cytogenomics for reproductive genetics and oncology, and read this press release about Phase Genomics’ new platform to detect chromosomal abnormalities. To learn more about Phase Genomics, be sure to follow them on Twitter, Facebook, LinkedIn and Instagram and keep up with our guests, Dr. Ivan Liachko on Twitter and LinkedIn, and Dr. Steve Eacker on Twitter and LinkedIn. Stay tuned for the next new episode of DNA Today on February 4, 2022 where we’ll be discussing mitochondrial disorders to kick off rare disease month! In the meantime, you can binge over 165 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to [email protected]. Aceragen is a rare disease biopharmaceutical company. Aceragen takes on rare, orphan diseases that typically have no approved treatments, and works to develop therapies to help patients. The needs of patients who suffer from under-served rare diseases drive Aceragen’s mission. Be sure to tune into our episode with Aceragen in February as we celebrate rare disease month! Learn more at aceragen.com. Aceragen working for a better life for patients with rare diseases. (SPONSORED) PerkinElmer Genomics is a state-of-the-art biochemical and molecular genetics laboratory that provides newborn screening and genomic testing services around the world. With over seven million newborns screened since 1994, PerkinElmer Genomics’ laboratory pairs decades of newborn screening experience with a leading-edge clinical genomics program to offer one of the world’s most comprehensive programs for detecting clinically significant genomic changes. Learn more at PerkinElmerGenomics.com. (SPONSORED) Do you want to connect with other people who have the same genetic variant as you? You should check out “Connect My Variant”, it’s an online resource that allows you to do just that. “Connect My Variant” also provides different avenues of informing your family of possible inherited risk of disease. This includes helping find where your variant came from and finding distant cousins that may also be at risk. The University of Washington has supported the “Connect My Variant” project in an effort to help patients and families understand where their unique genetic variants come from. Check out it at ConnectMyVariant.com. (SPONSORED)

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related